DNAprint Genomics (DNAG)

[ann441j]

From today's PR:

"It is important to protect the company's technologies and the revenue that can be derived from them," stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Our proprietary methods for marking gene sequences are especially important, because they are the key to developing theranostic drugs."

The patent provides legal protection for DNAPrint's status as one of few companies currently capable of performing objective, assumption-free haplotype analysis of DNA strands.

DNAPrint Genomics currently holds two other patents and has several others pending or in the hands of patent counsel.

Ann